Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arlene Chan

Showing results (41-50 of 86) with videos related to

Pageof 9
Sort By:
Vaccines|July 27, 2024
Evaluating Two Educational Interventions for Enhancing COVID-19 Knowledge and Attitudes in a Sample American Indian/Alaska Native PopulationMaya Asami Takagi, Simone T Rhodes, Jun Hwan Kim, et al.
Investigational New Drugs|June 27, 2013
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II studyDavid M Hyams, Arlene Chan, Celia de Oliveira, et al.
Clinical Breast Cancer|January 17, 2022
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 TrialGuy Jerusalem, Thomas E Delea, Migule Martin, et al.
Plos One|March 18, 2021
Decentralizing PrEP delivery: Implementation and dissemination strategies to increase PrEP uptake among MSM in Toronto, CanadaMaxime Charest, Malika Sharma, Allison Chris, et al.
BMC Health Services Research|July 5, 2018
Decentralizing the delivery of HIV pre-exposure prophylaxis (PrEP) through family physicians and sexual health clinic nurses: a dissemination and implementation study protocolMalika Sharma, Allison Chris, Arlene Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III studyJonas Bergh, Igor M Bondarenko, Mikhail R Lichinitser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancerLuca Gianni, Gilles H Romieu, Michail Lichinitser, et al.
The Lancet. Oncology|December 7, 2019
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trialRobert Coleman, Dianne M Finkelstein, Carlos Barrios, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast CancerSara M Tolaney, Solmaz Sahebjam, Emilie Le Rhun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancerDavid W Miles, Arlene Chan, Luc Y Dirix, et al.
Pageof 9

Showing results (41-50 of 86) with videos related to

Sort By:
Pageof 9
Vaccines|July 27, 2024
Evaluating Two Educational Interventions for Enhancing COVID-19 Knowledge and Attitudes in a Sample American Indian/Alaska Native PopulationMaya Asami Takagi, Simone T Rhodes, Jun Hwan Kim, et al.
Investigational New Drugs|June 27, 2013
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II studyDavid M Hyams, Arlene Chan, Celia de Oliveira, et al.
Clinical Breast Cancer|January 17, 2022
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 TrialGuy Jerusalem, Thomas E Delea, Migule Martin, et al.
Plos One|March 18, 2021
Decentralizing PrEP delivery: Implementation and dissemination strategies to increase PrEP uptake among MSM in Toronto, CanadaMaxime Charest, Malika Sharma, Allison Chris, et al.
BMC Health Services Research|July 5, 2018
Decentralizing the delivery of HIV pre-exposure prophylaxis (PrEP) through family physicians and sexual health clinic nurses: a dissemination and implementation study protocolMalika Sharma, Allison Chris, Arlene Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III studyJonas Bergh, Igor M Bondarenko, Mikhail R Lichinitser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancerLuca Gianni, Gilles H Romieu, Michail Lichinitser, et al.
The Lancet. Oncology|December 7, 2019
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trialRobert Coleman, Dianne M Finkelstein, Carlos Barrios, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast CancerSara M Tolaney, Solmaz Sahebjam, Emilie Le Rhun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancerDavid W Miles, Arlene Chan, Luc Y Dirix, et al.
Pageof 9